Angiogenesis, or the formation of new blood vessels from other pre-existing vessels, is essential for tumour growth, tumour progression and the subsequent appearance of metastasis in other organs. Given this, in recent years, antiangiogenic therapies have been aggressively developed as anticancer treatments. To this end, over 50 pharmacological inhibitors of angiogenesis can be found in various phases of clinical development at this time. Most of the targets for these compounds are various angiogenesis-inducing factors. One of the most important and most specific ones is the vascular endothelial growth factor (VEGF), which stimulates endothelial cell proliferation and migration and the formation of new blood vessels.